PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22893681-0 2012 Prevalence of acquired fosfomycin resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3. Fosfomycin 23-33 EsbL Escherichia coli 51-83 22893681-1 2012 OBJECTIVES: To investigate the prevalence of plasmid-mediated fosfomycin resistance determinants among extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae and their genetic environments. Fosfomycin 62-72 EsbL Escherichia coli 103-135 23198454-3 2012 OBJECTIVE: To determine the in vitro activity of fosfomycin against ESBL and non-ESBL-producing E. coli and K. pneumoniae uropathogens in Lebanon. Fosfomycin 49-59 EsbL Escherichia coli 81-85 23198454-3 2012 OBJECTIVE: To determine the in vitro activity of fosfomycin against ESBL and non-ESBL-producing E. coli and K. pneumoniae uropathogens in Lebanon. Fosfomycin 49-59 EsbL Escherichia coli 68-72 23198454-6 2012 RESULTS: The fosfomycin susceptibility for ESBL-producing vs. non-ESBL-producing isolates was 86% vs. 97% for E. coli and 62% vs. 78% for K. pneumoniae. Fosfomycin 13-23 EsbL Escherichia coli 43-47 23198454-6 2012 RESULTS: The fosfomycin susceptibility for ESBL-producing vs. non-ESBL-producing isolates was 86% vs. 97% for E. coli and 62% vs. 78% for K. pneumoniae. Fosfomycin 13-23 EsbL Escherichia coli 66-70 23198454-7 2012 This activity of fosfomycin among ESBL-EC and ESBL-KP was generally higher than cefepime (26% & 30%), ciprofloxacin (24% & 41%), Trimeth/sulfa (26% & 19%), Pip/taz (75% and 45%), gentamicin (45% & 42%), and tobramycin (32% & 26%). Fosfomycin 17-27 EsbL Escherichia coli 34-38 23198454-7 2012 This activity of fosfomycin among ESBL-EC and ESBL-KP was generally higher than cefepime (26% & 30%), ciprofloxacin (24% & 41%), Trimeth/sulfa (26% & 19%), Pip/taz (75% and 45%), gentamicin (45% & 42%), and tobramycin (32% & 26%). Fosfomycin 17-27 EsbL Escherichia coli 46-50 23198454-10 2012 CONCLUSION: Fosfomycin shows good activity, being higher against ESBL-producing E. coli than K. pneumoniae uropathogens in Lebanon. Fosfomycin 12-22 EsbL Escherichia coli 65-69 20129148-2 2010 We evaluated the evidence on fosfomycin as a treatment option for infections caused by members of the family Enterobacteriaceae with advanced resistance to antimicrobial drugs, including producers of extended-spectrum beta-lactamase (ESBL). Fosfomycin 29-39 EsbL Escherichia coli 234-238 20851815-0 2010 Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Fosfomycin 38-48 EsbL Escherichia coli 115-119 20851815-0 2010 Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Fosfomycin 67-77 EsbL Escherichia coli 115-119 20851815-1 2010 OBJECTIVES: To document fosfomycin susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC), analyse trends in fosfomycin use and investigate fosfomycin resistance in ESBL-EC isolated from urinary tract infections (UTIs). Fosfomycin 24-34 EsbL Escherichia coli 114-118 20851815-4 2010 In addition, the trend in fosfomycin resistance among ESBL-EC causing UTIs was determined in 9 of the 27 hospitals. Fosfomycin 26-36 EsbL Escherichia coli 54-58 20851815-7 2010 The overall rate of fosfomycin resistance was 9.1%, but varied according to ESBL type (5.6% of CTX-M-14 isolates, 5.1% of SHV-12 and 15.3% of CTX-M-15). Fosfomycin 20-30 EsbL Escherichia coli 76-80 20851815-9 2010 Predictors of infection with fosfomycin-resistant ESBL-EC were O25b/phylogroup B2 isolates, female gender and nursing home residence. Fosfomycin 29-39 EsbL Escherichia coli 50-54 20851815-13 2010 CONCLUSIONS: Key factors related to increased fosfomycin resistance in ESBL-EC causing UTIs could be the rapid growth in community use of fosfomycin, the widespread distribution of the 025b/B2 E. coli clone and the existence of a susceptible population comprising women residing in nursing home facilities. Fosfomycin 46-56 EsbL Escherichia coli 71-75 20851815-13 2010 CONCLUSIONS: Key factors related to increased fosfomycin resistance in ESBL-EC causing UTIs could be the rapid growth in community use of fosfomycin, the widespread distribution of the 025b/B2 E. coli clone and the existence of a susceptible population comprising women residing in nursing home facilities. Fosfomycin 138-148 EsbL Escherichia coli 71-75 20129148-5 2010 Using a provisional minimum inhibitory concentration susceptibility breakpoint of 64 mg/L or less, 1604 (96.8%) of 1657 Escherichia coli isolates producing ESBL were susceptible to fosfomycin. Fosfomycin 181-191 EsbL Escherichia coli 156-160 20129148-6 2010 Similarly, 608 (81.3%) of 748 Klebsiella pneumoniae isolates producing ESBL were susceptible to fosfomycin. Fosfomycin 96-106 EsbL Escherichia coli 71-75 20129148-7 2010 In two clinical studies, oral treatment with fosfomycin-trometamol was clinically effective against complicated or uncomplicated lower urinary tract infections caused by ESBL-producing E coli in, cumulatively, 75 (93.8%) of the 80 patients evaluated. Fosfomycin 45-66 EsbL Escherichia coli 170-174 19308743-0 2009 [In vitro activity of fosfomycin against ESBL-producing enterobacteria of urinary origin]. Fosfomycin 22-32 EsbL Escherichia coli 41-45 19308743-1 2009 In vitro activity of fosfomycin, compared with other antibiotics used for urinary tract infections (UTI), against extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates obtained from UTIs, was determined. Fosfomycin 21-31 EsbL Escherichia coli 148-152 19308743-2 2009 The activity of fosfomycin, co-trimoxazole, ciprofloxacin, nitrofurantoin, amoxicillin/clavulanic acid and gentamicin against 71 ESBL-producing E. coli clinical isolates and 13 ESBL-producing K. pneumoniae clinical isolates obtained from UTI was studied by the agar-dilution method or E-test. Fosfomycin 16-26 EsbL Escherichia coli 129-133 19255989-5 2008 The results showed excellent in vitro activity of the studied drugs against ESBL-producing K. pneumoniae with percent susceptibility of 100, 100, 100, 89.8, and 92.7 for ertapenem, imipenem, meropenem, fosfomycin, and colistin, respectively. Fosfomycin 202-212 EsbL Escherichia coli 76-80 19255989-8 2008 All studied drugs, except netilmicin, exhibited good activity against ESBL-producing Escherichia coli with 100% sensitivity for carbapenem, fosfomycin, colistin and 95.8% for piperacillin/tazobactam. Fosfomycin 140-150 EsbL Escherichia coli 70-74 19255989-17 2008 CONCLUSION: Carbapenems, fosfomycin, and colistin exhibited excellent in vitro activity against both ESBL-producing K. pneumoniae and E. coli. Fosfomycin 25-35 EsbL Escherichia coli 101-105 18423165-10 2008 The 68.6% of ESBL-producing E.coli were resistant to cotrimoxazole, 72.2% to ciprofloxacin vs 10.6% to nitrofurantoin and 1.9% to phosphomycin. Fosfomycin 130-142 EsbL Escherichia coli 13-17 18154548-3 2008 Fosfomycin continues to be active against the most common uropathogens; in a recent survey from Spain, among the 428 ESBL-producing isolates, the resistance rate of E. coli to fosfomycin was 0.3%, whereas the resistance rate of K. pneumoniae was 7.2%. Fosfomycin 0-10 EsbL Escherichia coli 117-121 18154548-3 2008 Fosfomycin continues to be active against the most common uropathogens; in a recent survey from Spain, among the 428 ESBL-producing isolates, the resistance rate of E. coli to fosfomycin was 0.3%, whereas the resistance rate of K. pneumoniae was 7.2%. Fosfomycin 176-186 EsbL Escherichia coli 117-121 18154548-4 2008 Other recent surveys, from other parts of the world, confirm the activity of fosfomycin against ESBL-producing E. coli. Fosfomycin 77-87 EsbL Escherichia coli 96-100 17194386-3 2006 METHODS: The in vitro activity of fosfomycin (FOS) was determined against 428 ESBL-producing strains, including 290 (68%) E. coli and 138 (32%) K. pneumoniae. Fosfomycin 34-44 EsbL Escherichia coli 78-82 17194386-12 2006 CONCLUSION: Fosfomycin showed maintained activity against ESBL-producing strains and did not present co-resistance with other antimicrobial groups. Fosfomycin 12-22 EsbL Escherichia coli 58-62 32840305-0 2020 Impact of reflex fosfomycin E-testing on the utilization of carbapenems for definitive extended-spectrum beta-lactamase Escherichia coli urinary tract infection treatment. Fosfomycin 17-29 EsbL Escherichia coli 87-119 17169640-5 2006 ESBL-producing E. coli showed a significant reduction in the susceptibility to most antimicrobials, although carbapenems and fosfomycin retained significant activity. Fosfomycin 125-135 EsbL Escherichia coli 0-4 16377714-0 2006 In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Fosfomycin 21-31 EsbL Escherichia coli 40-72 16377714-1 2006 The agar dilution, broth microdilution, and disk diffusion methods were compared to determine the in vitro susceptibility of 428 extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin. Fosfomycin 225-235 EsbL Escherichia coli 129-161 16377714-2 2006 Fosfomycin showed very high activity against all ESBL-producing strains. Fosfomycin 0-10 EsbL Escherichia coli 49-53 34804597-0 2021 Antimicrobial Susceptibilities of Urinary Extended-spectrum beta-lactamase Escherichia coli to Fosfomycin. Fosfomycin 95-105 EsbL Escherichia coli 42-74 34804597-2 2021 We aimed to determine the susceptibility profile of extended-spectrum beta-lactamase (ESBL) producing E. coli isolated from the urinary samples to fosfomycin and other antibiotics. Fosfomycin 147-157 EsbL Escherichia coli 52-84 34666660-6 2021 In this study, it was aimed to evaluate the utility of disk diffusion, agar dilution kit and automated MicroScan methods (Beckman Coulter, Brea, CA, ABD) for fosfomycin susceptibility of ESBL-producing enteric bacteria. Fosfomycin 158-168 EsbL Escherichia coli 187-191 34666660-17 2021 As a result; fosfomycin is thought to be an alternative drug option in the treatment of infections caused by especially carbapenem and colistin resistant bacteria, with its high activity on ESBL-producing enteric bacteria. Fosfomycin 13-23 EsbL Escherichia coli 190-194 34490146-9 2021 All ESBL-EC isolates were resistant to third-generation cephalosporin and quinolones and sensitive to carbapenem and fosfomycin. Fosfomycin 117-127 EsbL Escherichia coli 4-8 33045444-0 2020 In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae. Fosfomycin 9-19 EsbL Escherichia coli 83-87 33045444-2 2020 Recent studies reported the good in vitro activity of fosfomycin against ESBL and carbapenem-resistant Enterobacteriaceae. Fosfomycin 54-64 EsbL Escherichia coli 73-77 33045444-6 2020 RESULTS: Fosfomycin showed very good activity against ESBL-producing E.coli (88.6%). Fosfomycin 9-19 EsbL Escherichia coli 54-58 33045444-11 2020 CONCLUSIONS: When ESBL E. coli isolates are found to be susceptible to fosfomycin with automated systems, it is not necessary to verify these results with the AD reference method; while for resistant strains, the gradient test can be used. Fosfomycin 71-81 EsbL Escherichia coli 18-22 32840305-1 2020 PURPOSE: A protocol was started within a large health system to automatically test all confirmed extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli urine isolates for susceptibility to fosfomycin, an antibiotic not routinely included in such testing in most institutions. Fosfomycin 201-211 EsbL Escherichia coli 97-129 32799271-7 2020 Sensitivity rate of ESBL producing Escherichia coli to Fosfomycin was 96.5%, and 98.8% for ESBL negative Escherichia coli. Fosfomycin 55-65 EsbL Escherichia coli 20-24 32799271-8 2020 Sensitivity rate of ESBL producing Klebsiella pneumoniae to Fosfomycin was 70.5%, and 53.1% for ESBL negative Klebsiella pneumoniae. Fosfomycin 60-70 EsbL Escherichia coli 20-24 32380640-0 2020 Urinary Pharmacokinetic and Pharmacodynamic Profiles of Fosfomycin against Extended-Spectrum beta-Lactamase-Producing Escherichia coli with Canine Ex Vivo Modeling: A Pilot Study. Fosfomycin 56-66 EsbL Escherichia coli 75-107 32566057-9 2020 Fosfomycin MIC90 for ESBL-E. coli was 5.78 mug/mL. Fosfomycin 0-10 EsbL Escherichia coli 21-25 32380640-1 2020 Fosfomycin is a candidate drug for extended-spectrum beta-lactamase (ESBL)-producing bacteria, but its efficacy is yet to be investigated in dogs. Fosfomycin 0-10 EsbL Escherichia coli 35-67 32120467-8 2019 ABST of ESBL producers revealed high resistance rates for quinolones (41%) and >80% sensitivity for nitrofurantoin, fosfomycin, mecillinam, aminoglycosides and carbapenems. Fosfomycin 124-134 EsbL Escherichia coli 8-12 32120467-12 2019 >80% ESBL organisms show high sensitivity for aminoglycosides, carbapenems, nitrofurantoin, mecillinam and fosfomycin. Fosfomycin 115-125 EsbL Escherichia coli 5-9 32032026-1 2019 INTRODUCTION: We aimed to demonstrate if fosfomycin tromethamine (FT) treatment could be the treatment of choice in ESBL-producing Enterobacteriaceae strains as an alternative to carbapenem particularly in patients who we would like to treat on an outpatient basis. Fosfomycin 41-64 EsbL Escherichia coli 116-120 31258896-1 2019 Background: The aim of this study was to evaluate the efficacy of fosfomycin in the treatment of complicated urinary tract infections (cUTIs) caused by extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae. Fosfomycin 66-76 EsbL Escherichia coli 186-190 31258896-4 2019 In vitro susceptibility to fosfomycin of ESBL-producing Escherichia coli, Klebsiella pneumoniae and Citrobacter freundii isolates was tested according to the European Committee on Antimicrobial Susceptibility Testing methodology. Fosfomycin 27-37 EsbL Escherichia coli 41-45 31258896-11 2019 Conclusions: Fosfomycin may be a valid option for oral treatment of cUTIs caused by ESBL-producing pathogens. Fosfomycin 13-23 EsbL Escherichia coli 84-88 32032026-1 2019 INTRODUCTION: We aimed to demonstrate if fosfomycin tromethamine (FT) treatment could be the treatment of choice in ESBL-producing Enterobacteriaceae strains as an alternative to carbapenem particularly in patients who we would like to treat on an outpatient basis. Fosfomycin 66-68 EsbL Escherichia coli 116-120 32032026-11 2019 CONCLUSION: Oral fosfomycin tromethamine might be the treatment of choice in ESBL-producing enterobactericea related UTIs especially caused by Escherichia Coli. Fosfomycin 17-40 EsbL Escherichia coli 77-81 30766796-3 2019 Limited reports support the use of fosfomycin for chronic prostatitis by ESBL-producing bacteria. Fosfomycin 35-45 EsbL Escherichia coli 73-77 30766796-8 2019 Experience with fosfomycin for chronic prostatitis caused by ESBL-producing E. coli is limited to three case reports and two case series. Fosfomycin 16-26 EsbL Escherichia coli 61-65 30766796-10 2019 Accordingly, our report suggests that fosfomycin can be used as eradication therapy in a patient with a prior history of chronic prostatitis by ESBL-producing bacteria with recurring urinary infections after surgical treatment. Fosfomycin 38-48 EsbL Escherichia coli 144-148 29064348-2 2018 The purpose of this study was to evaluate the in vitro activity of fosfomycin against urinary ESBL-producing isolates of Enterobacteriaceae. Fosfomycin 67-77 EsbL Escherichia coli 94-98 29064348-7 2018 Of all the antibiotics tested, fosfomycin was the most active antimicrobial agent (97%) against the ESBL-positive isolates. Fosfomycin 31-41 EsbL Escherichia coli 100-104 29064348-8 2018 Fosfomycin maintained higher activity against ESBL-Escherichia coli than against ESBL-Klebsiella pneumoniae. Fosfomycin 0-10 EsbL Escherichia coli 46-50 29064348-11 2018 We showed that fosfomycin had a numerically higher susceptibility rate than the other antibiotics against the ESBL-producing isolates of the most common Enterobacteriaceae. Fosfomycin 15-25 EsbL Escherichia coli 110-114 29064348-12 2018 Given its low resistance rate and oral administration, fosfomycin may be deemed a promising antibiotic for the treatment of urinary tract infections caused by ESBL-producing Enterobacteriaceae. Fosfomycin 55-65 EsbL Escherichia coli 159-163 29924280-2 2018 Aiming to determine the sensitivity to fosfomycin, a study was conducted in ESBL-producing E. coli strains isolated from urine cultures at a hospital in Peru. Fosfomycin 39-49 EsbL Escherichia coli 76-80 28992981-10 2018 Fosfomycin and nitrofurantoin were very active on E. coli ESBL. Fosfomycin 0-10 EsbL Escherichia coli 58-62 29924280-5 2018 One hundred and ninety-two (192) (72.2%) strains of ESBL-producing E. coli strains sensitive to Fosfomycin were found. Fosfomycin 96-106 EsbL Escherichia coli 52-56 29924280-6 2018 It, therefore, follows that fosfomycin exhibits antimicrobial activity against ESBL-producing E. coli strains and that it could be considered a good treatment option for resistant strains. Fosfomycin 28-38 EsbL Escherichia coli 79-83 28457027-12 2017 A number of old antibiotic compounds such as Polymyxins, Fosfomycin, and Aminoglycosides are re-emerging as valuable alternatives for the treatment of ESBL producing bacteria. Fosfomycin 57-67 EsbL Escherichia coli 151-155 28456703-1 2017 Fosfomycin in combination with various antibiotics represents an excellent clinically efficacious regimen for the treatment of urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli. Fosfomycin 0-10 EsbL Escherichia coli 203-207 28456703-4 2017 Antimicrobial sensitivity testing indicated that 6.7% (24/356) of the ESBL-producing E. coli strains were resistant to fosfomycin. Fosfomycin 119-129 EsbL Escherichia coli 70-74 28456703-9 2017 The results indicate that presence of the fosA3 gene is the primary mechanism of fosfomycin resistance in ESBL-producing E. coli isolates in Wenzhou, China. Fosfomycin 81-91 EsbL Escherichia coli 106-110 27092771-7 2016 More than 95% of non extended-spectrum beta-lactamase (ESBL)-producing E. coli were susceptible to nitrofurantoin, fosfomycin, cefotaxime and aminoglycosides. Fosfomycin 115-125 EsbL Escherichia coli 55-59 26124169-1 2015 The aim of this study was to improve the understanding of the pharmacokinetic-pharmacodynamic relationships of fosfomycin against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains that have different fosfomycin MICs. Fosfomycin 111-121 EsbL Escherichia coli 130-162 27013000-8 2016 Two studies reported decreasing susceptibility of ESBL-producing E. coli to fosfomycin. Fosfomycin 76-86 EsbL Escherichia coli 50-54 26816887-2 2015 The current study was undertaken with a dual purpose, to provide an insight into the current scenario of the microorganisms causing UTI, their antimicrobial sensitivity patterns and also try and evaluate the activity of fosfomycin against E. coli, both ESBL producers as well as non-producers. Fosfomycin 220-230 EsbL Escherichia coli 253-257 26816887-12 2015 CONCLUSION: Fosfomycin showed good activity against both ESBL-producing and ESBL-negative E. coli isolates. Fosfomycin 12-22 EsbL Escherichia coli 57-61 26816887-12 2015 CONCLUSION: Fosfomycin showed good activity against both ESBL-producing and ESBL-negative E. coli isolates. Fosfomycin 12-22 EsbL Escherichia coli 76-80 26414659-13 2016 CONCLUSIONS: Overall, the in vitro susceptibility to nitrofurantoin, fosfomycin, mecillinam and temocillin was high, indicating that these drugs are good options for treating uncomplicated urinary tract infections caused by ESBL-producing E. coli. Fosfomycin 69-79 EsbL Escherichia coli 224-228 26349119-3 2015 Fosfomycin is active against most strains of Pseudomonas aeruginosa and several multidrug-resistant Enterobacteriaceae, e.g., Escherichia coli strains expressing extended spectrum beta-lactamases (ESBL) and Klebsiella pneumoniae strains with decreased susceptibilities to carbapenems. Fosfomycin 0-10 EsbL Escherichia coli 197-201 26026972-0 2015 Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Fosfomycin 198-208 EsbL Escherichia coli 34-66 25179392-3 2014 We conducted a retrospective study of 36 outpatients aged >18 years with dysuria or problems with frequency or urgency in passing urine; pyuria and a positive urine culture (10(5) cfu/ml) for ESBL producing Ec or Kp which is also resistant to nitrofurantoin, fosfomycin, quinolones and trimethoprim/sulfamethoxazole, between January 2013 and February 2014. Fosfomycin 262-272 EsbL Escherichia coli 195-199 25492650-2 2014 The aim of this study was to investigate in vitro activity of fosfomycin, presented as a favorable choice for the treatment of UTIs caused especially by extended-spectrum beta-lactamase (ESBL)-producing strains. Fosfomycin 62-72 EsbL Escherichia coli 187-191 25492650-11 2014 Fosfomycin resistance of ESBL-producing and non-producing isolates were 3% and 1%, respectively, indicating no significant difference between the two groups (p= 0.356). Fosfomycin 0-10 EsbL Escherichia coli 25-29 25492650-12 2014 According to fosfomycin MIC breakpoints defined by CLSI, 98.3% of ESBL-producing isolates and 100% of non-producing isolates were found susceptible to fosfomycin. Fosfomycin 13-23 EsbL Escherichia coli 66-70 25492650-12 2014 According to fosfomycin MIC breakpoints defined by CLSI, 98.3% of ESBL-producing isolates and 100% of non-producing isolates were found susceptible to fosfomycin. Fosfomycin 151-161 EsbL Escherichia coli 66-70 25492650-13 2014 According to EUCAST recommendations 98.3% of ESBL-producing isolates and 99.2% of non-producing isolates were found susceptible to fosfomycin. Fosfomycin 131-141 EsbL Escherichia coli 45-49 25492650-17 2014 It was concluded that fosfomycin which had a high activity against ESBL-producing isolates was an appropriate alternative antibiotic in the treatment of UTIs. Fosfomycin 22-32 EsbL Escherichia coli 67-71 23742831-8 2013 Extended-spectrum beta-lactamase (ESBL)-producing isolates displayed higher fosfomycin resistance rates than negative strains (19.2% vs. 2.9%). Fosfomycin 76-86 EsbL Escherichia coli 0-32 24421836-2 2013 Although limited in their indications, fosfomycin and tigecycline are potential agents to treat infections due to ESBL-producing organisms. Fosfomycin 39-49 EsbL Escherichia coli 114-118 24421836-8 2013 CONCLUSION: Although resistance to these antibiotics has previously been reported, the present study confirmed that isolates of ESBL-producing E coli from the Interior Health Region of British Columbia remain highly susceptible to both tigecycline and fosfomycin. Fosfomycin 252-262 EsbL Escherichia coli 128-132 23742831-8 2013 Extended-spectrum beta-lactamase (ESBL)-producing isolates displayed higher fosfomycin resistance rates than negative strains (19.2% vs. 2.9%). Fosfomycin 76-86 EsbL Escherichia coli 34-38 23742831-10 2013 CONCLUSIONS: Regardless of ESBL production, the excellent activity of fosfomycin against E. coli, Enterobacter spp, Serratia spp, and Citrobacter spp, indicates that the drug is a valuable therapeutic option for urinary tract infections, even those with co-trimoxazole- and ciprofloxacin-resistant isolates, but not in ESBL-producing Klebsiella spp, Pseudomonas spp, A. baumannii, and Proteus spp. Fosfomycin 70-80 EsbL Escherichia coli 319-323